AFASAK

AFASAK

A primary prevention study comparing low-dose aspirin to warfarin anticoagulation in preventing thromboembolic phenomena (stroke, TIA, or embolic complications) of chronic atrial fibrillation.
Conclusion Thromboembolism was much lower with warfarin (2.0% per year) than with aspirin (5.5% per year) or placebo.
Mentioned in ?
References in periodicals archive ?
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study.
Five randomized, primary stroke prevention trials in patients with AF (Veteran Affairs SPAF, (4) BAATAF, (5) AFASAK, (6) CAFA, (7) and SPINAF (8)) used their own risk stratification schemes.
Warfarin, aspirin ve plasebonun karsilastirildigi AFASAK, SPAF I, BAATAF, SPINAF, EAFT, SPAF II calismalarinda, warfarin ve aspirin tedavilerinin her birinin plaseboya gore strok riskini anlamli azalttigi, warfarinin ise aspirin ile karsilastirildiginda cok daha iyi sonuclar verdigini gostermistir (1).
Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study.